Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + AVD in Pediatric Advanced Hodgkin Lymphoma
2023-506415-18-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Takeda. Primary endpoints: Recommended dose of brentuximab vedotin in combination with AVD (Phase 1), Adverse events incidence through 30 days after last dose (Phase 1) and 6 more. Planned start Jan 2024; status: authorised.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2023-506415-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506415-18-00.